Studies indicate that NRAS-mutant melanoma may exhibit resistance to immune checkpoint inhibitors (ICIs), potentially stemming from changes in cell surface proteins crucial for T-cell response, akin to TP53-mutant tumors. This evidence concerns the gene NRAS and melanoma.